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ischaemic preconditioningIschemic heart disease (IHD) is the leading cause of death and disability worldwide. Therefore, novel therapeutic
targets for protecting theheart against acute ischemia/reperfusion injury (IRI) are required to attenuate cardiomyo-
cyte death, preserve myocardial function, and prevent the onset of heart failure. In this regard, a speciﬁc group of
mitochondrial proteins, which have been linked to familial forms of Parkinson's disease (PD), may provide novel
therapeutic targets for cardioprotection. In dopaminergic neurons of the substantia nigra, these PD proteins,
which include Parkin, PINK1, DJ-1, LRRK2, and α-synuclein, play essential roles in preventing cell death—through
maintaining normal mitochondrial function, protecting against oxidative stress, mediating mitophagy, and
preventing apoptosis. These rare familial forms of PDmay therefore provide important insights into the pathophys-
iology underlying mitochondrial dysfunction and the development of PD. Interestingly, these PD proteins are also
present in the heart, but their role inmyocardial health and disease is not clear. In this article, we review the role of
these PD proteins in the heart and explore their potential as novel mitochondrial targets for cardioprotection.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
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Ischemic heart disease (IHD) is the leading cause of death and
disability worldwide. The major clinical manifestations of IHD arise
from the detrimental effects of acute ischemia/reperfusion injury (IRI)
on the myocardium. Therefore, novel therapeutic targets for protecting
the heart against IRI are required to limit cardiomyocyte death, preserve
myocardial function and prevent the onset of heart failure.
In this regard, a speciﬁc group of mitochondrial proteins that have
been linked to familial forms of Parkinson's disease (PD) may providethe CC BY license (http://creativecommons.org/licenses/by/4.0/).
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of the substantia nigra, these PD proteins, which include Parkin, PINK1,
DJ-1, LRRK2, andα-synuclein, have been reported to play essential roles
in preventing cell death. This is achieved by maintaining normal
mitochondrial function, protecting against oxidative stress, mediating
mitophagy and preventing apoptosis. These rare familial PD proteins
may provide important insights into the pathophysiological mecha-
nisms underlying mitochondrial dysfunction and the development of
PD. Crucially, these PD proteins are also present in the heart, but their
role in myocardial health and disease is not clear. In this article, we
review the role of these PD proteins in the heart and as potential
therapeutic targets for cardioprotection.
2. Parkinson's disease
After Alzheimer's disease, PD is the second most common neurode-
generative disorder (de Lau & Breteler, 2006). The prevalence of PD in
industrialized countries is estimated at 0.3% of the entire population
(Nussbaum & Ellis, 2003) and approximately 1.0% of the population
over the age of 60 is affected (Abou-Sleiman et al., 2006). The disease
is expected to impose an increasing health, social and economic burden
on societies with aging populations. Clinically, PD is characterized by
rigidity, bradykinesia, resting tremor and postural instability. At the
subcellular level, there is a loss of dopaminergic neurons particularly
in the substantia nigra pars compacta region of the brain. Most PD
cases are sporadic with only a small proportion (about 5–10%) being
attributable to genetic mutations—these result in rare familial forms of
PD (Mounsey & Teismann, 2011).
Interestingly, several clinical studies have reported an increased risk
of cardiovascular disease in PD patients, with a lower life expectancy
than the general population (Morgante et al., 2000), with heart failure
(Fernandez & Lapane, 2002) and IHD (Ben-Shlomo & Marmot, 1995)
being common causes of death in elderly PD patients. The prevalence
of heart failure in elderly PD patients was shown in one cross-
sectional study to be over twice that of age-matched non-PD patients
(Zesiewicz et al., 2004). The reasons for this are unclear but may relateFig. 1. Schematic diagram showing the interplay between PINK1, Parkin, and DJ-1. (A) PINK1 a
Parkin. Parkin then ubiquinates its substrates leading to the localization of P62 and LC3 for subse
and coordinate mitochondrial dynamics in a parallel fashion. (C) Parkin and DJ-1 interact withto several factors including the disease process itself, cardiac sympa-
thetic denervation (Goldstein et al., 2000), PD medications (associated
with heart valve disease) (Pritchett et al., 2002), and concurrent
co-morbidities (such as age hypertension, diabetes, IHD and so on).
Several of the mitochondrial proteins which have been linked to
PD are present in the heart and are reviewed in the subsequent
sections.
3. Parkin
3.1. Introduction
Parkin (PARK2) was the ﬁrst gene to be associated with autosomal
recessive PD (Kitada et al., 1998). It encodes a 52 kDa protein, which
is found in the liver, kidney, testis, brain, skeletal muscle and heart
(Kitada et al., 1998). Parkin is an E3 ubiquitin ligase which catalyzes
the transfer of ubiquitin from an E2 ubiquitin-conjugating enzyme to a
protein substrate in a process called ubiquitination (reviewed in
Winklhofer, 2014). Under basal conditions, Parkin is located mainly in
the cytosol, where its ubiquitin ligase activity is inhibited. Following
cellular stress, Parkin translocates to damaged mitochondria in a
PINK1-dependent manner to ubiquitinate a number of mitochondrial
substrates mediating mitochondrial fragmentation, degradation and
mitophagy (Matsuda et al., 2010).
3.1.1. Parkin-mediated mitophagy
PINK1 and Parkin have been shown tomediate the selective removal
of damaged mitochondria by inducing mitophagy (reviewed in
Winklhofer, 2014) (Fig. 1). In healthy mitochondria with normal
membrane potential, PINK1 is imported into the mitochondria and
becomes degraded by proteolysis. However, in damaged mitochondria,
the depolarization of themembrane potential allows the stabilization of
PINK1 in the outer mitochondrial membrane (OMM), where it phos-
phorylates ubiquitin resulting in the activation of Parkin (Iguchi et al.,
2013; Koyano et al., 2014). The latter then ubiquitinates mitochondrial
proteins (such as Mfn1 and Mfn2 and other proteins) (Gegg et al.,ccumulation leads to phosphorylation of mitochondrial proteins leading to recruitment of
quentmitophagy. (B) PINK1 and DJ-1 are recruited to themitochondrial outermembrane
each other in an oxidative stress-dependent manner.
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the initiation ofmitophagy. An additionalmechanism for Parkin translo-
cation has recently been described in whichMfn2 is phosphorylated by
PINK1 and acts as a receptor for Parkin (Chen et al., 2013).
3.2. Parkin and the heart
Parkin is found to be expressed in the heart and recent experimental
studies are beginning to elucidate its potential roles in this organ.
Most of its effects in the heart appear to relate to its beneﬁcial effects
on maintaining mitochondrial health.
3.2.1. Preconditioning cardioprotection
The heart can be protected against acute IRI by subjecting it to one
or more episodes of brief ischemia/reperfusion—a cardioprotective
phenomenon which has been termed ischemic preconditioning (IPC)
and which manifests either immediately (classical IPC) or 24 hours
later (delayed IPC) (Murry et al., 1986; Hausenloy, 2013; Hausenloy &
Yellon, 2013). In 2011, Huang et al. (2011) were the ﬁrst to investigate
a role for Parkin in the heart. They found that the endogenous
cardioprotective phenomenon of IPC induced the mitochondrial
translocation of Parkin in ex vivo rat and in vivo murine hearts
(Huang et al., 2011). Crucially, Parkin-deﬁcient mice were resistant to
IPC, suggesting that Parkin is required to mediate the cardioprotection
elicited by IPC (Huang et al., 2011). Kubli et al. (2013) showed that
cardiac size and function were normal under baseline conditions in
Parkin-deﬁcient mice when compared to wild-type mice. However,
Parkin-deﬁcient hearts were more susceptible to ischemic injury
following permanent left coronary artery occlusion as evidenced by
larger infarct sizes, worse left ventricular remodeling and increased
mortality (Kubli et al., 2013). Together, these ﬁndings suggest that
Parkin might play a role in maintaining mitochondrial function under
stress conditions; while the role of Parkin as a mediator of IPC is not
clear, it may be related to the former's role in mediating mitophagy.
3.2.2. Mitophagy
A Parkin-independent mitophagy pathway involving Dynamin-
related protein 1 (Drp1) has recently been described (Kageyama et al.,
2014), which may in part explain the lack of cardiac phenotype in
Parkin-deﬁcient hearts in the study by Kubli and colleagues (Kubli
et al., 2013). A separate study by Song et al. (2015) reported that endog-
enous Parkin is rare in normal hearts but upregulated in response to
Drp1 ablation leading to a cardiomyopathy phenotype. Interestingly,
concomitant deletion of both Parkin and Drp1 reversed this phenotype
demonstrating the complex interplay between Parkin and mitochon-
dria. Hoshino et al. (2013) have investigated the role of Parkin-
mediated mitophagy in the aged heart and in the heart subjected to
doxycycline cardiotoxicity. In both these settings, they found that cyto-
solic p53 prevented the mitochondrial translocation of Parkin thereby
attenuating the protective mitophagic response (Hoshino et al., 2013).
3.2.3. Mitochondrial dynamics
Mitochondrial dynamics have also been implicated in cardiomyopa-
thy secondary to impaired mitophagy. Parkin-knockout Drosophila
displayed enlarged hollow “donut” mitochondria, which could be
rescued by cardiomyocyte-speciﬁc Parkin expression and by also sup-
pressing cardiomyocyte mitochondrial fusion. The latter also reversed
the dilated cardiomyopathy phenotype. The group thereby inferred
that Parkin ablation supressed normal mitophagic organelle elimina-
tion; this resulted in a contamination of abnormal mitochondria,
which were able to fuse with normal mitochondria to precipitate
cardiomyopathy. By suppressing mitochondrial fusion factors and
therefore interrupting the feed-forward pathway of mitochondrial con-
tamination, Bhandari et al. prevented this cardiomyocytemitochondrial
pool contamination and found that end-organ dysfunction could poten-
tially be delayed (Bhandari et al., 2014). Although mitochondrialmorphology by electron microscopy revealed disorganized clusters of
small mitochondria, therewas no difference inmitochondrial respirato-
ry function and mitochondrial permeability transition pore (MPTP)
opening susceptibility (Kubli et al., 2013).
4. PINK1
4.1. Introduction
Mutations in PTEN-induced kinase 1—PINK1 (PARK6), a
mitochondrially targeted serine/threonine kinase, are the second
most frequent cause of autosomal recessive, young-onset PD after
Parkin (PARK2) (Abramov et al., 2011). The protein is expressed in the
brain, heart, skeletal muscle, liver, kidney, pancreas and testes. PINK1
is a mitochondrial protein whose kinase domain localizes in the OMM.
Its kinase activity is critical for its protective effects—indeed, most
mutations are found in the serine/threonine kinase domain, which sug-
gests that loss of kinase activity plays a crucial part in the pathogenesis
of PINK1-linked PD (Zhou et al., 2008; Hatano et al., 2009). PINK1 has
been identiﬁed as a protective agent against oxidative stress-induced
apoptosis—one of the mechanisms underlying this is through its phos-
phorylation of the mitochondrial chaperone TNF-receptor-associated
protein 1, (TRAP1) (Pridgeon et al., 2007).
Experiments have shown that the expression of PINK1 in vitro
protects against exogenous stressors such as MPP+, rotenone and
staurosporine (Petit et al., 2005; Haque et al., 2008; Sandebring et al.,
2009). Conversely, siRNA ablation of PINK1 enhanced cell death in the
presence of certain toxins. Fibroblasts from patients with mutations in
PINK1 displayed signiﬁcant bioenergetics defects, such as reduced
mitochondrial membrane potential, altered redox state, and enhanced
sensitivity to calcium stimulation. Similarly, mitochondria isolated
from PINK1-KO ﬂies have been shown to have reduced respiratory
function (Liu et al., 2011).
Mitochondrial morphology is also impaired when PINK1 is
suppressed—there is an increase in fragmented mitochondria in PINK1
knockdown mammalian cultured cells (Deng et al., 2005; Exner et al.,
2007; Lutz et al., 2009). Additionally, transgenic Drosophila with
PINK1 promotes mitochondrial ﬁssion in dopaminergic neurons, while
complete ablation of PINK1 leads to excessive fusion (Yang et al., 2008).
4.2. PINK1 and the heart
Siddall et al. (2008)were theﬁrst to postulate a cardioprotective role
for PINK1 in the heart. Since then, Billia et al. (2011) have demonstrated
that levels of PINK1 were signiﬁcantly reduced in end-stage human
heart failure and that PINK1 activity is necessary for correct postnatal
myocardial development. The authors found that PINK1-deﬁcient
mice had mitochondrial impairment; in particular, they were more
sensitive toward Reactive oxygen species (ROS)-dependent depolariza-
tion of themitochondrial membrane potential, had decreased oxidative
phosphorylation andmoremitochondrial swelling. Our grouphave con-
ﬁrmed similar mitochondrial ﬁndings in isolated cardiomyocytes fol-
lowing simulated IRI (Siddall et al., 2013). Furthermore, we showed
that mice genetically ablated for PINK1 developed signiﬁcantly larger
myocardial infarcts following an episode of sustained 35 minutes of re-
gional ischemia and 30 minutes of reperfusion compared to their wild-
type counterparts, whilemice heterozygous for PINK1 had intermediate
infarct sizes (Siddall et al., 2013).
Billia et al. (2011) also described greater oxidative stress and higher
levels of lipid peroxidation in PINK1-KO mice. Recent work has centered
on cardiolipin, amitochondrial phospholipid that is crucial tomaintaining
normal cardiac function. It had been found that ALCAT1, a lysocardiolipin
acyltransferase that catalyzes pathological remodeling of cardiolipin
in response to oxidative stress in cardiomyopathy, leads to ROS produc-
tion andmitochondrial dysfunction (Li et al., 2010). Ablation of ALCAT1
dramatically increased expression of PINK1, which supports a
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thy (Liu et al., 2012).
5. DJ-1
5.1. Introduction
In 1997, Nagakubo et al. (1997) ﬁrst identiﬁed DJ-1 to be a novel
oncogene capable of transforming mouse NIH3T3 cells in cooperation
with activated ras. The human DJ-1 protein has 189 amino acids
(20 kDa protein) and belongs to the ThiJ/PfpI family where it functions
as a dimer (Tao & Tong, 2003). It has been shown to be present in a
number of human tissues including the brain, liver, skeletalmuscle, kid-
ney, testes, as well as the heart (Nagakubo et al., 1997). In 2003, it was
discovered that deletion and point mutations in the DJ-1 gene on chro-
mosome 1p36 (Leu166Pro or L166P) were responsible for the PARK7
familial form of PD (van Duijn et al., 2001; Bonifati et al., 2003). The
L166P mutant form of DJ-1 disrupts the C-terminal region, which is
required for its dimerization and subsequent activation (Olzmann
et al., 2004), thereby increasing its degradation (Hulleman et al., 2007).
The ﬁrst study to implicate DJ-1 as a neuroprotective protein was by
Yokota and co-workers in 2003 (Yokota et al., 2003), whodemonstrated
that ablating DJ-1 increased cell death induced by oxidative stress,
endoplasmic reticulumstress and proteosome inhibition,whereas over-
expressing wild-type DJ-1 but not the L166P DJ-1 mutant protected
against cell death inmouse Neuro2a cells and human embryonic kidney
293T cells. The neuroprotective effect which is absent in the L166P DJ-1
mutant has been conﬁrmed by a number of subsequent studies in
response to oxidative stress (Miller et al., 2003; Moore et al., 2003;
Takahashi-Niki et al., 2004; Ren et al., 2012; Chang et al., 2014),
proteosome inhibition (Moore et al., 2003) and apoptotic stimuli
(Moore et al., 2003; Ren et al., 2012). Neurons in mice lacking DJ-1
were also demonstrated to be more susceptible to oxidative stress
(Kim et al., 2005b). Injection of wild-type DJ-1 into murine brains has
been reported to reduce cerebral infarct size in both ischemic and
endothelin-1-induced murine models of stroke (Aleyasin et al., 2007;
Yanagisawa et al., 2008). The role that DJ-1 plays in the pathophysiology
of PD remains unclear, but the beneﬁcial effects of this protein in terms
of mediating neuroprotection are summarized below:
• Anti-oxidant properties: Oxidative stress is known to be a critical
determinant in the pathogenesis of PD. In 2001, Mitsumoto et al.
(Mitsumoto & Nakagawa, 2001) ﬁrst demonstrated that DJ-1 may
act as an endogenous indicator of oxidative stress, suggesting that it
may play a role as an anti-oxidant. Subsequent studies have demon-
strated that the Cys-106 residue on the DJ-1 protein is the site of
oxidation, resulting in the formation of cysteine-sulphinic acid, a
process which appears critical to its mitochondrial translocation and
neuroprotective effect (Canet-Avilés et al., 2004) (Fig. 1).
• Anti-apoptotic effects: DJ-1 has been reported to be present in the
nucleus and can modulate transcription (Nagakubo et al., 1997; Niki
et al., 2003; Junn et al., 2005, 2009). In 2005, it was proposed by
Junn and co-workers (Junn et al., 2005) that DJ-1 reduced cell death
by interacting with and sequestering the death-associated protein,
Daxx, in the nucleus, thereby preventing its cytosolic translocation
and activation of the apoptosis signal-regulating kinase 1 (ASK1), a
pro-apoptotic protein which activates JNK1/2. More recent studies
have suggested that DJ-1 may inhibit oxidative stress-induced apo-
ptotic cell death by interacting with ASK1 directly (Im et al., 2010;
Mo et al., 2010; Klawitter et al., 2013) and preventing its dissociation
with Thioredoxin 1, a factor which inhibits ASK1 activity under basal
conditions and reducing JNK activity (Im et al., 2010). Furthermore,
DJ-1 has been reported to prevent apoptotic cell death by activating
and phosphorylating the anti-apoptotic protein kinase, Akt, by sup-
pressing PTEN activity (Kim et al., 2005a; Aleyasin et al., 2010). Con-
versely, DJ-1 ablation resulted in down-regulation of the PI3K-Aktpathway and cell death (Kim et al., 2005a; Aleyasin et al., 2010). Re-
cent studies suggest that DJ-1 may actually stabilize hypoxia-
inducible factor through its activation of the PI3K-Akt pathway
(Vasseur et al., 2009).
• Effects on mitochondrial respiratory function: Impaired mitochondrial
respiration arising from complex I inhibition has been implicated
as a causative factor in mitochondrial dysfunction and the production
of oxidative stress observed in PD. Under basal conditions, endoge-
nous DJ-1 is present in the cytosol and nucleus (Canet-Avilés et al.,
2004; Taira et al., 2004; Zhang et al., 2005). Upon oxidation, DJ-1
translocates from the cytosol to the OMM, a processwhich is required
for its neuroprotective effect (Junn et al., 2009). Interestingly, a more
detailed study has suggested that endogenous DJ-1 is present in the
mitochondrial inter-membranous space and matrix of neuronal cells
(Zhang et al., 2005). It has been suggested that DJ-1 binds to electron
transport chain complexes (NDUFA4 and ND1) and is required for
the latter's normal function such that knockdown of DJ-1 inhibits
complex I activity (Hayashi et al., 2009). Experimental studies have
demonstrated that overexpressing wild-type DJ-1 protected against
rotenone-induced (a complex I inhibitor) induced mitochondrial
dysfunction and that the ablation of endogenous DJ-1 increased the
susceptibility of neurons to rotenone and other complex I inhibitors
(Mullett & Hinkle, 2009; Thomas et al., 2011; Gao et al., 2012). A
recent study has also shown that mouse embryonic (MEFs) lacking
DJ-1 had impaired mitochondrial respiration due to complex I
inhibition, increasedmitochondrial oxidative stress, reducedmito-
chondrial membrane potential, more fragmented mitochondria,
and impaired mitophagy, ﬁndings which conﬁrmed that DJ-1 is
required for normal mitochondrial function (Krebiehl et al.,
2010). The beneﬁcial effect of DJ-1 on mitochondrial function and
autophagy appears to be parallel to the PINK-1/Parkin pathway,
two other proteins in which mutations are associated with
Parkinson's disease (Thomas et al., 2011; reviewed in Winklhofer
& Haass, 2010; Chu, 2011).
• Effects on mitochondrial morphology: Impaired mitochondrial DJ-1
deﬁciency leads to altered mitochondrial morphology and in-
creases the production of ROS as a result of altered mitochondrial
dynamics (Irrcher et al., 2010). DJ-1 has also been shown to pro-
mote endoplasmic reticulum (ER)-mitochondria tethering in
HeLa cells, albeit mitochondrial elongation was actually induced
(Ottolini et al., 2013). Similar ﬁndings were also observed in neu-
ronal cells (Wang et al., 2012). Overexpression of DJ-1 in the HL-
1 cardiac cell line induces mitochondrial elongation and decreases
sensitivity to mPTP opening. Although mice deﬁcient in DJ-1 have
more fragmented mitochondria, the hearts of these mice do not
display any apparent cardiac phenotype (Dongworth et al., 2014).
Nevertheless, the effect of DJ-1 on mitochondrial morphology
seems to be species and cell-type dependent (Hao et al., 2010).
• Effects on mitochondrial turnover: The regulation of mitochondrial
turnover is vital for cellular homeostasis and survival (Farré et al.,
2009) and DJ-1 may also be involved in the quality control of
mitochondria; there is dysfunctional lysosomal degradation and
reduced mitochondrial clearance in DJ-1 KO MEFs (Krebiehl et al.,
2010). Autophagy is a lysosomal degradation process that
maintains sufﬁcient ATP levels during periods of energy limitation
(Vasseur et al., 2009) and plays a protective role in the early stages
of apoptosis as part of the cellular attempt at self-rescue (Jellinger
& Stadelmann, 2000; González-Polo et al., 2007a, 2007b). There is
reduced basal autophagy encountered in DJ-1 −/− MEFs cells
(Krebiehl et al., 2010).
• Effects on mitochondrial biogenesis: Impaired mitochondrial DJ-1
also promotes the transcriptional activity of peroxisome
proliferator-activated receptor-γ co-activator 1α (PGC-1α), an
agent involved in mitochondrial biogenesis and the oxidative
stress response (Zhong & Xu, 2008). DJ-1 inhibits the SUMOylation
of a transcriptional repressor of PGC-1α, pyrimidine tract-binding
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levels of manganese superoxide dismutase, which aids in oxidative
stress defence (Zhong & Xu, 2008).
• Interactions with other Parkinson's proteins: DJ-1-dependent
mitochondrial defects can be rescued by addition of a cell-
permeable glutathione precursor or Parkin/PINK1 overexpression
(Thomas et al., 2011). Recently, DJ-1 was found to negatively regulate
PINK1-dependent Parkin translocation to depolarized mitochondria in
neurons, as a result of its ability to control Reactive oxygen species
(ROS) generation (Joselin et al., 2012). DJ-1 can act on mitochondria
to prevent the aggregation and toxicity of α-synuclein in an
oxidation-dependent manner (Batelli et al., 2008; Giaime et al., 2012).
Parkin and DJ-1 may interact under conditions of oxidative stress
(Moore et al., 2005). In cells overexpressing PINK1, DJ-1 binds
to PINK1 and increases its steady-state levels (Tang et al., 2006).
PINK1 and Parkin have also been found to rescue the phenotype of
DJ-1−/− cells (Irrcher et al., 2010) (Fig. 1).
5.2. DJ-1 and the heart
DJ-1 is known to be present in the heart and only recently has its
role in this tissue been investigated. Under baseline conditions,mice lack-
ing DJ-1 do not appear to have an obvious cardiac phenotype in terms of
heart/body weight ratios, cardiomyocyte cross-section, cardiac size and
function on echocardiography when compared to wild-type mice, sug-
gesting a non-essential role of this mitochondrial protein under physio-
logical conditions (Billia et al., 2013; Dongworth et al., 2014). However,
under conditions of cellular stress, hearts deﬁcient in DJ-1 appear to
be more susceptible to a number of pathological stresses. Neonatal
murine cardiomyocytes overexpressing DJ-1 have been shown to
be protected against cell death induced by oxidative stress, whereas
cardiomyocytes deﬁcient in DJ-1 were more susceptible to ROS-
induced apoptotic cell death (Billia et al., 2013).
5.2.1. Ischemia/reperfusion injury
A number of recent experimental studies have suggested that DJ-1
protects the heart against acute IRI (Bitar et al., 2012; Liu et al., 2014).
Proteomic analysis of murine hearts subjected to in vivo acute IRI
demonstrated that protein levels of DJ-1 were down-regulated after
30 minutes of ischemia, a change which persisted 60 minutes into
reperfusion but which was restored by 120 minutes of reperfusion.
These changes inmyocardial DJ-1 protein expressionwerenot associated
with changes in mRNA expression of DJ-1 implicating degradation in
DJ-1 protein levels in response to acute IRI. It has been shown that
DJ-1 becomes unstable and is degraded in response to oxidative stress,
a process which is exacerbated by the down-regulation of the antioxi-
dant transcriptional master regulator Nrf2—whether this is the mecha-
nism for DJ-1 down-regulationwith IRI remains to be determined (Bitar
et al., 2012; Liu et al., 2014).
Overexpression of DJ-1 in H9c2 myotubes and the HL-1
cardiomyocytes has been shown to protect cells against simulated
ischemia (Yu et al., 2013) and simulated IRI (Dongworth et al., 2014).
The protective effects of DJ-1 were associated with inhibition of MPTP
opening and increasedmitochondrial elongation inHL-1 cardiomyocytes,
markers of cardioprotection (Dongworth et al., 2014). Importantly,
cells overexpressing non-functional mutant forms of DJ-1 (L166P and
Cys106A) were not protected against simulated IRI (Dongworth et al.,
2014).
The role of endogenous DJ-1 in the setting of acute IRI has also been
recently examined. Billia et al. (2013) reported that DJ-1-deﬁcient mice
had larger infarct sizes and greater levels of interstitial ﬁbrosis 4 weeks
following an episode of acute IRI; these ﬁndings were associated with a
signiﬁcant increase in the number of apoptotic cardiomyocytes in the
peri-infarct area 72 hours following IRI when compared with wild-type animals. Dongworth et al. (2014) also reported an acute increase
in MI size in DJ-1-deﬁcient mice subjected to 45 minutes of myocardial
ischemia and 24 hours of reperfusion, ﬁndings which were associated
with mitochondrial fragmentation on electron microscopy, but no
differences in calcium-inducedMPTP opening,mitochondrial respiratory
function, or myocardial ATP levels, when compared to wild-type mice.
In summary, these ﬁndings suggest that DJ-1 is regulated in the setting
of acute IRI and it may protect the heart against IRI and therefore be a
novel target for cardioprotection.
The diabetic heart ismore susceptible to acute IRI and cardiac failure.
Liu et al. (2013) have investigated the role ofDJ-1 in thediabetic heart in
the setting of Ischemic Postconditioning (IPost) the cardioprotection in-
duced by interruptingmyocardial reperfusionwith short-lived episodes
of ischemia) (Zhao et al., 2003; Hausenloy, 2013). They found that
protein levels of DJ-1 were reduced in the diabetic rat heart (attributed
to increased myocardial oxidative stress) and these ﬁndings were
associated with a blunted response to the MI-limiting effects of IPost
(Liu et al., 2013).
5.2.2. Cardioprotection
The role of DJ-1 as a potential mediator of IPC has been investigated
in recently published experimental studies. Lu et al. (2012) found that
subjecting rat heart-derived H9c2 cells to a standard hypoxic precondi-
tioning stimulus resulted, 24 hours later, in the up-regulation of both
ERK1/2 (a known mediator of delayed IPC and DJ-1, as well as lower
levels of oxidative stress and cell death. Importantly, inhibition of
Erk1/2 prevented the up-regulation of DJ-1 and the ablation of DJ-1 ab-
rogated the protection associated with preconditioning, suggesting that
hypoxic preconditioning mediates its protective effect through the
Erk1/2-dependent activation of DJ-1 (Lu et al., 2012). We have found
that mice lacking DJ-1 were resistant to the infarct-limiting effects of
classical IPC, suggesting that DJ-1 may also act as a mediator of classical
IPC in an in vivomurine MI model (Dongworth et al., 2014). The mech-
anism through which DJ-1 mediates the cardioprotection elicited by
classical IPC is unclear and remains to be investigated. The role of DJ-1
in IPost, has been investigated by Liu et al. (2013)who found that a stan-
dard IPost protocol was able to increase DJ-1 protein levels in the non-
diabetic rat heart but not diabetic ones due to impaired signaling
through the PI3K-Akt pathway and increased oxidative stress.
5.2.3. Pressure-overload left ventricular hypertrophy
The role of DJ-1 has been investigated in the setting of left ventricu-
lar hypertrophy (Billia et al., 2013). Mice deﬁcient in DJ-1 have been
demonstrated to be more susceptible to pressure-overload left
ventricular hypertrophy induced by both total aortic constriction and
Angiotensin II (Billia et al., 2013). This ﬁnding was associated with im-
paired cardiac contractile function, increased interstitial ﬁbrosis, upregu-
lated mRNA expression of known pathological cardiac proteins (such as
atrial natriuretic factor and brain natriuretic peptide), Erk1/2 activation,
β-myosin heavy chain, oxidative DNA damage, impaired mitochondrial
function, and less angiogenesis (with reduced mRNA expression of
VEGF and angiopoietin) (Billia et al., 2013).
5.2.4. Heart failure
The role of DJ-1 in the development of heart failure has been recently
investigated—oxidative stress is a known mediator of heart failure
andDJ-1 has been demonstrated to have an anti-oxidant effect. Further-
more, Billia et al. (2013) demonstrated that protein levels of DJ-1 in left
ventricular tissue were down-regulated in patients with end-stage
human heart failure compared to normal healthy controls. The
reduction in DJ-1 protein levels was likely to be due to post-
translationalmodiﬁcation as therewas no difference inmRNA expression
between the two groups (Billia et al., 2013). Interestingly, Klawitter et al.
(2013) found that protein levels of DJ-1 were elevated in myocardial tis-
sue from patients with end-stage ischemic heart failure compared to pa-
tients with end-stage dilated cardiomyopathy and control patients; this
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(Klawitter et al., 2013). The reason for this difference in DJ-1 protein ex-
pression is not clear but was attributed to a cellular response to stress
(Klawitter et al., 2013).
6. LRRK2
6.1. Introduction
LRRK2 is a multi-domain protein that harbors a kinase and a GTPase
domain in multi-vesicular bodies and in autophagic vesicles (Korr et al.,
2006). LRRK2 resides mainly in the cytoplasm and is partially localized
to the mitochondria. It is associated with membranes, such as
mitochondria, ER and synaptic vesicles (Vitte et al., 2010). The
G2019S mutation is the most common genetic cause of PD. Autosomal
dominant mutations in LRRK2 are associated with both familial and
late-onset PD and patients have clinical symptoms and pathology
typical of sporadic PD (Mortiboys et al., 2010).
6.1.1. Effects on mitochondria
Patients with the G2019S mutation in LRRK2 have reduced mito-
chondrial membrane potential and decreased total intracellular ATP
levels (Mortiboys et al., 2010). The expression of the G2019S mutation
in ﬁbroblast and neuroblastoma cells in mouse brain was associated
with mitochondrial uncoupling, decreased mitochondrial membrane
potential and increased oxygen utilization both basally and under
oligomycin-inhibited conditions. These ﬁndings are also consistent
with defective oxidative phosphorylation resulting in decreased cellular
ATP levels demonstrated by Mortiboys et al. (2010). The decreased
mitochondrial membrane potential and normal maximal oxygen
utilization rates implied an increased permeability of the inner mito-
chondrial membrane (IMM) to protons; however, the mPTP was not
found to be involved as suggested by lack of increased ROS or death
in vitro (Papkovskaia et al., 2012).
6.2. LRRK2 and the heart
LRRK2 mRNA has been detected in the heart at lower levels than in
the brain (Zimprich et al., 2004). Interestingly, a recent study showed
that there were no differences in the hearts of LRRK2 wild-type and
knockout mice in terms of histopathology and ultrastructure (Baptista
et al., 2013). A case study has recently reported a patient with LRRK2
mutation displaying features of cardiac sympathetic denervation,
baroreﬂex-sympathoneural and baroreﬂex-cardiovagal failure
(Goldstein et al., 2007; Gehrke et al., 2010). Unlike in idiopathic PD,
heart rate variability was not reduced in LRRK2-PD; this implies a rela-
tive sparing of pathologic involvement of the autonomic innervation of
the heart (Joers & Emborg, 2014).
7. α-synuclein
7.1. Introduction
This is a small, acidic protein composed of 140 amino acid residues.
It is a soluble monomeric protein, with a predominantly cytosolic
location, although a fraction has been identiﬁed in the mitochondria
(Cole et al., 2008). Point mutations in the α-synuclein gene (PARK1)
(Polymeropoulos, 1997) have been described as causes of familial PD;
allele triplication of wild-typeα-synuclein genemutation leads to auto-
somal dominant PD (Singleton et al., 2004).
7.1.1. Effects on mitochondria
• Mitochondrial bioenergetics: Abnormal mitochondria are found in
transgenic mice overexpressing mutant α-synuclein (Song et al.,
2004). It is targeted to the IMMwhere it bindsmitochondrial complex
1 and impairs its function (Liu et al., 2009). One study found thatin vitro incubation of rat brain mitochondria with recombinant human
α-synuclein led to dose-dependent loss of mitochondrial transmem-
brane potential without an effect on the activities of the respiratory
chain complex. This suggested that α-synuclein may impair mitochon-
drial bioenergetics through a direct effect on mitochondrial mem-
branes. (Banerjee et al., 2010). In transgenic animals overexpressing
A53T ofα-synuclein speciﬁcallywithin dopaminergic neurons, the pro-
tein localized to the mitochondria as monomers and oligomers (Chinta
et al., 2010), where the oligomers led to a selective inhibition of com-
plex I function and also enhanced mitophagy under stress conditions.
• Mitochondrial dynamics: α-synuclein has been shown to interfere with
mitochondrial dynamics by disturbance of mitochondrial fusion, with
its overexpression in cells leading to mitochondrial fragmentation
(Kamp et al., 2010; Nakamura et al., 2011). Nevertheless, there have
also been other studies citing different effects ofα-synuclein in regulat-
ing mitochondrial morphology, for instance no effects observed under
physiological conditions (Zhu et al., 2012), age-dependent regulation
of mitochondrial dynamics (Xie & Chung, 2012), or promoting fusion
(Guardia-Laguarta et al., 2014).
• Axonal transport of mitochondria: α-synuclein is also thought to disrupt
the transport of mitochondria by affecting the polymerization and de-
polymerization of tubulin, whichmediate the distribution of mitochon-
dria within the neuron (Zhou et al., 2010). While the exact mechanism
through which it achieves this is unknown, it is believed that the two
proteins interact in some way. Disruption of the microtubule network
could signiﬁcantly impact the mitochondrial dynamics and the
mitophagy of damaged mitochondria (Protter et al., 2012).
• ER stress: ER stress has been detected in dopaminergic neurons of the
substantia nigra bearing α-synuclein inclusions in the brains of
patients affected by PD, indicating that ER stress is involved in sporadic
PD (Jiang et al., 2010). Furthermore, the ER stress observed closely
correlated with the accumulation and aggregation of α-synuclein
(Jiang et al., 2010). Elevated α-synuclein levels have been found to
block ER to Golgi membrane trafﬁcking and cause ER stress (Cooper
et al., 2006; Thayanidhi et al., 2010), raising the possibility that
α-synuclein-induced ER stress might play a role in precipitating
mitochondrial stress.
7.2. α-synuclein and the heart
Autonomic dysfunctionmay be a feature of PD and symptoms of this
include chronic constipation, urinary urgency and incontinence (Niimi
et al., 1999). One study investigating a family, the “Iowa kindred” who
have AD parkinsonism with a triplication of the normal (not mutant)
α-synuclein gene (Singleton et al., 2003) found that cardiac sympathet-
ic denervation co-segregated with parkinsonism in this kindred. The
overexpression of the normal α-synuclein resulted in both loss of
dopamine-producing cells in the nigro-striatal system in the brain as
well as loss of norepinephrine-producing cells in the sympathetic cardiac
system (Singleton et al., 2004). Recently, Navarro-Otano and colleagues
have shown that abnormal α-synuclein aggregates are present in neu-
rons and nerveﬁbers (i.e. peripheral autonomic nervous system) of epi-
cardial tissue samples obtained during cardiac surgery in over 90
subjects without parkinsonism (Navarro-Otano et al., 2013). The au-
thors speculated that this could be a sign of early cardiac involvement
in pre-motor PD.
8. Mitochondrial Parkinson's proteins as therapeutic targets
Evidence is emerging that some familial Parkinson's proteins play a
protective role in the heart (see Table 1 and Fig. 1). It is imperative
that mechanisms are sought to explain the associations between PD and
cardiovascular disease, in order to better develop therapeutics to target
the respective diseases. Small molecule modulators of such proteins
Table 1
Potential involvement of Parkinson-disease proteins in various cardiac conditions.
Parkinson-disease protein Cardiac condition
Parkin Acute ischemia/reperfusion injury
PINK1 Acute ischemia/reperfusion injury
Heart failure, cardiac development
DJ-1 Acute ischemia/reperfusion injury
Left ventricular hypertrophy, heart failure,
diabetic heart
LRRK2 Heart failure?
α-synuclein Heart failure?
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which several of the proteins are involved (Zhou et al., 2011).
A recent study has identiﬁed several DJ-1-binding small molecule
compounds which bind to the Cys-106 region within DJ-1 maintain
activation of DJ-1 protein, thereby protecting cells against oxidative
stress-induced death (Miyazaki et al., 2008). This approach is already
being pursued in the ﬁeld of neurodegeneration; following 48 hours
of treatment with the histone deacetylase inhibitor, 4-sodium
phenylbutyrate in the N27 dopamine cell line, levels of DJ-1 were
increased by 300% and cells were rescued from oxidative stress (Zhou
et al., 2011). Another study reported that the intrastriatal pre-injection
of a DJ-1 modulator, UCP0054278, inhibited neurodegeneration arising
from 90 minutes of middle cerebral artery occlusion and reperfusion in
rats (Yanagida et al., 2009). Similar efforts should be applied toward
developing and testing such compounds in the heart to investigate
possible cardioprotective beneﬁts.
The ability to generate patient-speciﬁc induced pluripotent stem
cells (iPSCs) (Takahashi & Yamanaka, 2006) is also extremely exciting
for the development and evaluation of novel therapeutics. Human
iPSCs present an unprecedented opportunity to study disease-speciﬁc
differences at a personalized basis and can be genetically engineered
to carry mutations of speciﬁc Parkinson proteins. These iPSCs can then
be differentiated into desired lineages including cardiomyocytes and
subsequently used for drug screening, which takes into accountFig. 2. This schematic diagram illustrates the effects of Parkinson's disease-related proteins in the
α-synuclein in the innermitochondrial membrane (IMM) leads to excessivemitochondrial frag
which will eventually fragment should the stress conditions be prolonged. (A3) The fragmen
peroxidation, ROS, ER-stress, and cell death increase. Conversely, in the right panel (B), up-reg
of mitophagy in ischemic pre-conditioning (IPC) and reduction of infarct size. (B1) PINK1 phosp
for mediation of mitochondrial fragmentation and (B3) mitophagy. (B4) Increased PINK1/Parkiindividual drug responses within a patient population. The validity of
this approach has been exempliﬁed by the successful application of
human iPSCs in various diseases (Itzhaki et al., 2011; Yazawa et al.,
2011; Sun et al., 2012).
9. Summary and conclusions
Given that aging is a signiﬁcant contributor to both Parkinson's
disease and cardiac disease, the occurrence of both these conditions is
set to rise. Recent data suggest that the mitochondrial Parkinson's pro-
teins Parkin, PINK1, DJ-1, LRRK2 and α-synuclein are present in the
heart and studies are beginning to elucidate their role (see Table 1 and
Fig. 2 for summary). There is emerging evidence that PINK1 and DJ-1
may act as potentialmediators of cardioprotection; themechanisms un-
derlying this protective effect are not clear but may relate to their ben-
eﬁcial effects on mitochondrial function. They therefore represent
potential therapeutic targets for treating patients with IHD. These PD
proteins also appear to have beneﬁcial effects in other cardiac diseases
such as left ventricular hypertrophy andheart failure but further studies
are required to identify the underlying mechanisms.
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